Business Context and Reporting Period
Company: ARDELYX, INC. (Nasdaq: ARDX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of tenapanor-based therapies. Its primary products are IBSRELA (for irritable bowel syndrome with constipation) and XPHOZAH (for reducing serum phosphorus in chronic kidney disease patients on dialysis). The company operates in a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $94,473 | $74,114 |
| Net Loss | $(37,605) | $(41,144) |
| Net Loss Per Share (Basic & Diluted) | $(0.15) | $(0.17) |
| Cash and Cash Equivalents | $31,209 | $67,999 |
| Short-term Investments | $206,865 | $196,690 |
| Total Liquid Funds | $238,074 | $264,689 |
| Long-term Debt (Principal) | $200,000 | $200,000 |
| Accumulated Deficit | $(984,544) | $(926,484) |
Operating Cash Flow: Net cash used in operating activities was $32.2 million for Q1 2026, compared to $38.5 million in Q1 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 27% year-over-year, driven primarily by a 38% increase in net product sales.
- IBSRELA: Net sales surged 58% to $70.1 million, attributed to higher demand, increased prescriber awareness, and a higher net price.
- XPHOZAH: Net sales remained flat at $23.3 million. Growth in non-Medicare channels was offset by the impact of XPHOZAH being included in the End-Stage Renal Disease Prospective Payment System (ESRD PPS) on January 1, 2025, which eliminated Medicare Part D coverage.
- Licensing Revenue Decline: Licensing revenue dropped 99% to $51,000 from $5.0 million in Q1 2025. The prior year included a one-time $5.0 million milestone payment from Fosun Pharma upon NDA approval in China.
- Expense Increases:
- Selling, General and Administrative (SG&A): Increased 23% to $102.3 million due to commercialization costs supporting IBSRELA growth and increased headcount.
- Research and Development (R&D): Increased 35% to $20.2 million, driven by external expenses for the Phase 3 ACCEL trial evaluating tenapanor for chronic idiopathic constipation (CIC).
- Cost of Sales: Decreased 61% to $4.8 million. This reduction was primarily due to the full recognition of the $75.0 million AstraZeneca royalty obligation in the prior year, which is no longer impacting current costs.
Guidance, Outlook, Risks, and Unusual Items
- Debt Restructuring (Subsequent Event): On April 28, 2026, Ardelyx entered into a Sixth Amendment to its Loan Agreement. This refinanced a portion of outstanding debt into a new Term H Loan, extended the maturity date to July 1, 2030, and reduced the collective interest rate to 4.55% plus the greater of 1-month SOFR or 3.5%.
- Regulatory Risk (XPHOZAH): The inclusion of XPHOZAH in the ESRD PPS has materially impacted revenue growth. The company is litigating against CMS regarding this inclusion, but the lack of Medicare Part D coverage is expected to result in a lower pace of revenue growth compared to pre-2025 expectations.
- Pipeline Progress: The Phase 3 ACCEL trial for tenapanor in CIC patients dosed its first patient in January 2026. Topline data is expected in the second half of 2027.
- Liquidity: Management believes current cash, cash equivalents, and short-term investments ($238.1 million) are sufficient to fund operations for at least one year. The company has an additional $100 million available under its credit facility (Term F and G loans) with draw deadlines in June and December 2026.
- Legal Proceedings: Several shareholder derivative and securities class actions were dismissed or settled in 2025 and early 2026. As of March 31, 2026, no pending litigation is expected to have a material adverse effect.
Investor Verification Checklist
- XPHOZAH Revenue Trajectory: Verify the extent to which the ESRD PPS inclusion continues to suppress Medicare sales and whether non-Medicare growth is sufficient to offset this loss.
- Debt Covenants and Interest Rates: Review the specific terms of the Sixth Amendment to the Loan Agreement (Exhibit 10.3) to confirm the new interest rate floor and maturity extension details.
- IBSRELA Gross-to-Net (GTN) Adjustments: Monitor the increasing GTN adjustment percentage (36.3% in Q1 2026 vs. 29.9% in Q1 2025) to understand the impact of rebates and returns on net revenue.
- Cash Burn Rate: Assess the sustainability of the current operating cash burn (~$32 million per quarter) against the $238 million liquid cash position and the timeline for achieving cash flow positivity.
- ACCEL Trial Enrollment: Track the progress of the Phase 3 CIC trial enrollment, as success here is critical for expanding the IBSRELA addressable market.